Post Profile

Optimal Management for NSCLC Patients with Brain Metastases

A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer (NSCLC) with brain metastases to determine the best option for treatmen...
read more


Related Posts

New Drug Approved For Treatment Of Non Small Cell Lung Cancer In Specific Patient Population

Health : Medical News Today

Lung Cancer Alliance (LCA) applauds the Food and Drug Administration (FDA) approval of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) who are ALK positive. The drug was approved based on data from two clinical trials, ...

Different Approach Suggested After Progression In NSCLC Patients

Health : Medical News Today

Right now, the best known treatment for patients with metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase gene rearrangements (ALK) or epidermal growth factor receptor mutations (EGFR) is crizotinib or EGFR...

Afatinib shows clinical benefit for lung cancer patients with brain metastases

Academics / General Science : Science Codex

DENVER - Non-small cell lung cancer (NSCLC) patients with common epidermal growth factor (EGFR) mutations and brain metastases showed improved progression-free survival (PFS) and response from the EGFR tyrosine kinase inhibitor (TKI...

Analysis Finds Select Group of Stage IV Lung Cancer Patient Population Achieves Long-Term Survival After Aggressive Treatments

Health : Newswise Medical News

A large, international analysis of patients with stage IV non-small cell lung cancer (NSCLC) indicates that a patient's overall survival (OS) rate can be related to factors including the timing of when metastases develop and lymph n...

Moffitt Cancer Center Researchers Discover Link between Inherited Genetic Variations, Outcomes of Non-Small Cell Lung Cancer Patients

Health : Newswise Medical News

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Patients diagnosed with NSCLC have a poor prognosis, with a 5-year survival rate of only 16 percent. Researchers at Moffitt Cancer Center hope to improve NSC...


Copyright © 2016 Regator, LLC